R Squared’s Anavex Life Sciences AVXL Stock Holding History

R Squared’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-950	Closed	-$10.2K	–	407
2024 Q4	$10.2K	Buy	+950	New	+$7.31K	0.01%	1148

Other funds holding AVXL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NWAM LLC Mercer Island, Washington $2B AUM 34.81% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

R Squared's AVXL Position: Q1 2025 in Review

R Squared sold out of Anavex Life Sciences (AVXL) in Q1 2025, closing a stake of 950 shares — an estimated $10.2K sold.

R Squared first reported a position in AVXL in Q4 2024 and held it in 1 quarter. The position peaked at $10.2K in Q4 2024. 181 funds tracked by Wall St. Rank hold AVXL as of Q1 2025.

R Squared reported no remaining Anavex Life Sciences position as of Q1 2025 after selling out during the quarter.
R Squared sold 950 Anavex Life Sciences shares in Q1 2025, an estimated $10.2K.
R Squared first reported a position in Anavex Life Sciences in Q4 2024 and held it in 1 quarter.
R Squared's Anavex Life Sciences position peaked at $10.2K in Q4 2024.
181 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.